JP2020516663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516663A5 JP2020516663A5 JP2019556183A JP2019556183A JP2020516663A5 JP 2020516663 A5 JP2020516663 A5 JP 2020516663A5 JP 2019556183 A JP2019556183 A JP 2019556183A JP 2019556183 A JP2019556183 A JP 2019556183A JP 2020516663 A5 JP2020516663 A5 JP 2020516663A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydronaphthalene
- dioxo
- methoxy
- methylidene
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 10
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 claims 8
- -1 3-methoxy-1,4-dioxo-1,4-dihydronaphthalene-2-yl Chemical group 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- HVWUGMMHPTXECQ-ZHACJKMWSA-N (2e)-n-methoxy-2-[(3-methoxy-1,4-dioxonaphthalen-2-yl)methylidene]pentanamide Chemical compound C1=CC=C2C(=O)C(\C=C(/CCC)C(=O)NOC)=C(OC)C(=O)C2=C1 HVWUGMMHPTXECQ-ZHACJKMWSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 101710180995 Endonuclease 1 Proteins 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 229960002438 carfilzomib Drugs 0.000 claims 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 2
- 108010021331 carfilzomib Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960003649 eribulin Drugs 0.000 claims 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 230000033116 oxidation-reduction process Effects 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762486033P | 2017-04-17 | 2017-04-17 | |
| US62/486,033 | 2017-04-17 | ||
| PCT/US2018/027786 WO2018194976A1 (en) | 2017-04-17 | 2018-04-16 | Prevention and reversal of inflammation induced dna damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516663A JP2020516663A (ja) | 2020-06-11 |
| JP2020516663A5 true JP2020516663A5 (enExample) | 2021-04-30 |
Family
ID=63856081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556183A Pending JP2020516663A (ja) | 2017-04-17 | 2018-04-16 | 炎症によって誘起されるｄｎａ損傷の阻止及び回復 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190117602A1 (enExample) |
| EP (1) | EP3440047A4 (enExample) |
| JP (1) | JP2020516663A (enExample) |
| CA (1) | CA3060266A1 (enExample) |
| WO (1) | WO2018194976A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020514349A (ja) * | 2017-03-20 | 2020-05-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| JP2022513193A (ja) * | 2018-12-17 | 2022-02-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 消化管障害及びその症状の治療 |
| TW202426420A (zh) | 2022-09-14 | 2024-07-01 | 美商歐考菲爾製藥公司 | Ａｐｘ３３３０的鹽和酯及其治療用途 |
| CN119097711A (zh) * | 2024-09-11 | 2024-12-10 | 山东大学齐鲁医院 | Ape1抑制剂在制备治疗鼻窦炎药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0801949A1 (en) * | 1996-04-15 | 1997-10-22 | Eisai Co., Ltd. | Hypoglycemic quinone derivative |
| JPH1067653A (ja) * | 1996-06-17 | 1998-03-10 | Eisai Co Ltd | 関節疾患治療剤 |
| EP0813866A3 (en) * | 1996-06-17 | 1999-01-20 | Eisai Co., Ltd. | Therapeutic agent for joint diseases |
| US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| EP2203161B1 (en) * | 2007-09-26 | 2018-05-09 | Indiana University Research and Technology Corporation | Quinone derivatives, pharmaceutical compositions, and uses thereof |
| WO2010074675A1 (en) | 2008-12-23 | 2010-07-01 | Board Of Regents Of The University Of Texas System | Inflammation targeting particles |
| GB201020397D0 (en) | 2010-12-02 | 2011-01-12 | Univ Nottingham | Compounds |
| WO2012148889A1 (en) | 2011-04-28 | 2012-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of human apurinic/apyrimidinic endonuclease 1 |
| MX357284B (es) * | 2011-05-26 | 2018-07-04 | Univ Indiana Res & Tech Corp | Compuestos de quinona para tratar enfermedades mediadas por ape1. |
| US20140128398A1 (en) * | 2011-06-03 | 2014-05-08 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
| CN107184572B (zh) | 2017-03-09 | 2020-07-28 | 中山大学 | 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用 |
-
2018
- 2018-04-16 CA CA3060266A patent/CA3060266A1/en active Pending
- 2018-04-16 US US16/092,816 patent/US20190117602A1/en not_active Abandoned
- 2018-04-16 WO PCT/US2018/027786 patent/WO2018194976A1/en not_active Ceased
- 2018-04-16 EP EP18788150.3A patent/EP3440047A4/en active Pending
- 2018-04-16 JP JP2019556183A patent/JP2020516663A/ja active Pending
-
2020
- 2020-04-16 US US16/850,436 patent/US11351130B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516663A5 (enExample) | ||
| Cui et al. | Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction | |
| JP2024133475A5 (enExample) | ||
| JP2020502157A5 (enExample) | ||
| JP2019536805A5 (enExample) | ||
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2018514549A5 (enExample) | ||
| JP2016513097A5 (enExample) | ||
| JP2014532647A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2007536311A5 (enExample) | ||
| JP2019532051A5 (enExample) | ||
| CY1109070T1 (el) | Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη | |
| JP2016515586A5 (enExample) | ||
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| JP2019522032A5 (enExample) | ||
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| Bhaskar et al. | Comparison of transdermal diclofenac patch with oral diclofenac as an analgesic modality following multiple premolar extractions in orthodontic patients: a cross over efficacy trial | |
| JP2019517587A5 (enExample) | ||
| RU2008152341A (ru) | Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии | |
| Gupta et al. | Combating inadequate anesthesia in periapical infections, with sodium bicarbonate: a clinical double blind study | |
| JP2020529995A5 (enExample) | ||
| JP2015522077A5 (enExample) | ||
| JP2014534229A5 (enExample) |